NVS Novartis AG

   By Jessica Sier 
 

Novartis AG said Monday that it has acquired U.S.-based startup Amblyotech for an undisclosed sum.

The Swiss biotech company will partner with Ubisoft and McGill University to further develop a treatment of amblyopia, a lazy-eye disorder.

Amblyotech offers active-gaming and passive-video technology to train the eyes to view an image in full, said Novartis.

The Swiss company aims to develop Amblyotech's software into a medical device and conduct a proof of concept study.

Write to Jessica Sier at jessica.sier@wsj.com

(END) Dow Jones Newswires

April 20, 2020 01:50 ET (05:50 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.